GlobeStar Therapeutics Corporation (GSTC)
USD 0.0
(-16.67%)
USD 0.0
(-16.67%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 6724.00 USD | 10.75% |
| 2022 | -1.26 Million USD | 85.1% |
| 2021 | -9.09 Million USD | -3046.39% |
| 2020 | -302.34 Thousand USD | 4.14% |
| 2019 | -314.23 Thousand USD | 10.56% |
| 2018 | -713.13 Thousand USD | 21.68% |
| 2017 | -583.19 Thousand USD | 94.01% |
| 2016 | -2.77 Million USD | -1288.55% |
| 2015 | -675.62 Thousand USD | -27.75% |
| 2014 | -425.73 Thousand USD | 15.86% |
| 2013 | -584.19 Thousand USD | 46.66% |
| 2012 | -944.96 Thousand USD | -1646.54% |
| 2011 | -54.1 Thousand USD | -2503.71% |
| 2010 | -2078.00 USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -167.58 Thousand USD | -7.51% |
| 2024 Q3 | -193.35 Thousand USD | -15.38% |
| 2024 Q1 | -155.87 Thousand USD | 45.84% |
| 2023 Q3 | -1.27 Million USD | -795.8% |
| 2023 Q2 | -142.05 Thousand USD | 8.49% |
| 2023 Q1 | -155.24 Thousand USD | 47.37% |
| 2023 FY | - USD | 10.75% |
| 2023 Q4 | -287.78 Thousand USD | 77.39% |
| 2022 Q1 | -312.75 Thousand USD | 92.53% |
| 2022 Q2 | -662.31 Thousand USD | -111.77% |
| 2022 FY | - USD | 85.1% |
| 2022 Q4 | -294.96 Thousand USD | -100.06% |
| 2022 Q3 | -147.43 Thousand USD | 77.74% |
| 2021 Q4 | -4.18 Million USD | 6.59% |
| 2021 Q2 | -469.28 Thousand USD | -679.64% |
| 2021 Q3 | -4.48 Million USD | -855.39% |
| 2021 FY | - USD | -3046.39% |
| 2021 Q1 | -60.19 Thousand USD | 53.46% |
| 2020 FY | - USD | 4.14% |
| 2020 Q1 | -73.32 Thousand USD | -18.82% |
| 2020 Q2 | -51.26 Thousand USD | 30.09% |
| 2020 Q4 | -129.32 Thousand USD | -167.06% |
| 2020 Q3 | -48.42 Thousand USD | 5.53% |
| 2019 Q2 | -70.66 Thousand USD | 45.34% |
| 2019 Q3 | -53.74 Thousand USD | 23.95% |
| 2019 Q4 | -61.71 Thousand USD | -14.83% |
| 2019 Q1 | -129.27 Thousand USD | -16.56% |
| 2019 FY | - USD | 10.56% |
| 2018 Q3 | -69.72 Thousand USD | -92.63% |
| 2018 Q1 | -128.69 Thousand USD | 78.84% |
| 2018 FY | - USD | 21.68% |
| 2018 Q4 | -110.91 Thousand USD | -59.08% |
| 2018 Q2 | -36.19 Thousand USD | 71.88% |
| 2017 FY | - USD | 94.01% |
| 2017 Q4 | -608.21 Thousand USD | -668.06% |
| 2017 Q3 | -79.18 Thousand USD | 33.93% |
| 2017 Q2 | -119.86 Thousand USD | 49.39% |
| 2017 Q1 | -236.83 Thousand USD | 0.0% |
| 2016 Q3 | -24.78 Thousand USD | 74.03% |
| 2016 FY | - USD | -1288.55% |
| 2016 Q2 | -95.42 Thousand USD | 15.97% |
| 2016 Q1 | -113.56 Thousand USD | 45.79% |
| 2015 Q2 | -144.5 Thousand USD | -58.81% |
| 2015 FY | - USD | -27.75% |
| 2015 Q1 | -90.99 Thousand USD | -17.93% |
| 2015 Q4 | -209.48 Thousand USD | -116.4% |
| 2015 Q3 | -96.8 Thousand USD | 33.01% |
| 2014 Q4 | -77.15 Thousand USD | 32.92% |
| 2014 Q2 | -96.89 Thousand USD | 29.11% |
| 2014 FY | - USD | 15.86% |
| 2014 Q3 | -115.01 Thousand USD | -18.7% |
| 2014 Q1 | -136.67 Thousand USD | 50.33% |
| 2013 Q1 | -54.12 Thousand USD | -5.88% |
| 2013 Q4 | -275.15 Thousand USD | -125.85% |
| 2013 FY | - USD | 46.66% |
| 2013 Q3 | -121.82 Thousand USD | 8.45% |
| 2013 Q2 | -133.07 Thousand USD | -145.86% |
| 2012 Q4 | -51.12 Thousand USD | 92.92% |
| 2012 Q3 | -722.21 Thousand USD | -602.1% |
| 2012 Q2 | -102.86 Thousand USD | -49.59% |
| 2012 Q1 | -68.76 Thousand USD | -112.07% |
| 2012 FY | - USD | -1646.54% |
| 2011 Q2 | -2100.00 USD | 2.33% |
| 2011 Q1 | -2150.00 USD | 0.0% |
| 2011 Q3 | -17.42 Thousand USD | -729.95% |
| 2011 Q4 | -32.42 Thousand USD | -86.04% |
| 2011 FY | - USD | -2503.71% |
| 2010 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | 100.009% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | 100.113% |
| SQZ Biotechnologies Company | -64.14 Million USD | 100.01% |
| Evofem Biosciences, Inc. | -17.37 Million USD | 100.039% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | 99.993% |
| Mesoblast Limited | -62.38 Million USD | 100.011% |
| Propanc Biopharma, Inc. | -1.53 Million USD | 100.438% |
| Genus plc | 73.7 Million USD | 99.991% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | 100.102% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | 100.19% |
| Marizyme, Inc. | -34.28 Million USD | 100.02% |
| ContraFect Corporation | -64.99 Million USD | 100.01% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | 100.077% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | 100.149% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | 100.48% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | 100.254% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | 100.289% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | 101.298% |
| Accustem Sciences Inc. | -3.74 Million USD | 100.179% |
| RVL Pharmaceuticals plc | -48.22 Million USD | 100.014% |
| EV Biologics, Inc. | -1.26 Million USD | 100.531% |
| Q BioMed Inc. | -617.62 Thousand USD | 101.089% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | 99.812% |
| Neon Bloom, Inc. | -632.4 Thousand USD | 101.063% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | 100.294% |
| Biomind Labs Inc. | -1.03 Million USD | 100.65% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 9.87 Million USD | 99.932% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | 100.094% |
| Skye Bioscience, Inc. | -13.54 Million USD | 100.05% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | 100.452% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 126.896% |
| Arch Therapeutics, Inc. | -3.88 Million USD | 100.173% |
| IMV Inc. | -35.52 Million USD | 100.019% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 100.042% |
| Curative Biotechnology, Inc. | -2.5 Million USD | 100.269% |
| GB Sciences, Inc. | -1.41 Million USD | 100.474% |
| Alpha Cognition Inc. | -9.7 Million USD | 100.069% |
| HST Global, Inc. | -5303.00 USD | 226.796% |
| CSL Limited | 4.78 Billion USD | 100.0% |
| Halberd Corporation | -74.27 Thousand USD | 109.052% |
| Enzolytics Inc. | -2.12 Million USD | 100.317% |
| Resverlogix Corp. | -11.74 Million USD | 100.057% |
| Affymax, Inc. | -14.29 Million USD | 100.047% |
| SYBLEU INC | -141.57 Thousand USD | 104.75% |
| Nuo Therapeutics, Inc. | -3.06 Million USD | 100.22% |
| argenx SE | -216.02 Million USD | 100.003% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | 100.012% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | 99.447% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | 100.449% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | 98.225% |
| AVAX Technologies, Inc. | -6.11 Million USD | 100.11% |
| Zenith Capital Corp. | -8.6 Million USD | 100.078% |
| Genscript Biotech Corporation | -248.71 Million USD | 100.003% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | 138.597% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | 100.275% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | 103.82% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | 100.017% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | 100.232% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | -1.04 Million USD | 100.643% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | -1.74 Million USD | 100.384% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | 100.35% |
| BioStem Technologies, Inc. | -7.55 Million USD | 100.089% |
| ONE Bio Corp. | 13.61 Million USD | 99.951% |
| Reve Technologies, Inc. | -181.08 Thousand USD | 103.713% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | -2.05 Million USD | 100.327% |
| Agentix Corp. | -1.37 Million USD | 100.49% |
| LadRx Corporation | 412.28 Thousand USD | 98.369% |
| Cell Source, Inc. | -4.27 Million USD | 100.157% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | 101.831% |
| Regen BioPharma, Inc. | 1.46 Million USD | 99.541% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | 100.718% |
| NovAccess Global Inc. | -1.03 Million USD | 100.65% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | 99.924% |
| Itoco Inc. | -1.86 Million USD | 100.36% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | 101.771% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | 100.603% |
| Kadimastem Ltd | -2.62 Million USD | 100.256% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | 102.812% |
| CytoDyn Inc. | -18.02 Million USD | 100.037% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | 108.508% |
| Mobile Lads Corp. | -2.24 Million USD | 100.3% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | 154.984% |
| Qrons Inc. | -40.08 Thousand USD | 116.776% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | 101.384% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | 98.725% |
| Rebus Holdings, Inc. | -951 Thousand USD | 100.707% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | 100.633% |
| International Stem Cell Corporation | 202 Thousand USD | 96.671% |
| Bioxytran, Inc. | -3.82 Million USD | 100.176% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | 112.774% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | 100.273% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | -35.86 Million USD | 100.019% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | -45 Thousand USD | 114.942% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | 100.246% |
| Neutra Corp. | -181.24 Thousand USD | 103.71% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | 100.033% |
| PureTech Health plc | -11.62 Million USD | 100.058% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | 100.033% |
| IXICO plc | -707 Thousand USD | 100.951% |
| IntelGenx Technologies Corp. | -7.68 Million USD | 100.087% |
| Gelesis Holdings, Inc. | -48.34 Million USD | 100.014% |
| CSL Limited | 4.73 Billion USD | 100.0% |
| Cellectis S.A. | -92.63 Million USD | 100.007% |